Naloxonum Hydrochloricum Wzf (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naloxonum Hydrochloricum Wzf, is an opioid antagonist presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It reverses the effects of opioid overdose in emergency settings and is used by healthcare professionals worldwide.\n\nGNH India supplies Naloxonum Hydrochloricum Wzf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Naloxone Hydrochloride acts on the opioid receptor pathway to counteract opioid toxicity.\n\n- Opioid overdose: rapidly restores normal respiration and consciousness in patients with life‑threatening opioid intoxication.\n- Opioid‑induced respiratory depression: reverses breathing suppression during procedural sedation.\n- Acute opioid toxicity: mitigates severe central nervous system depression caused by accidental or intentional opioid exposure.

Naloxone is generally well tolerated, but adverse reactions can occur.\n\nCommon Side Effects:\n- Nausea: mild to moderate upset stomach.\n- Vomiting: occasional emesis following reversal.\n- Sweating: increased perspiration during recovery.\n- Tremor: transient shaking of limbs.\n- Headache: mild headache after administration.\n- Hypertension: temporary rise in blood pressure.\n\nSerious or Rare Side Effects:\n- Cardiac arrhythmia: irregular heart rhythm in susceptible patients.\n- Seizure: rare convulsive episodes, especially with high‑dose opioid dependence.\n- Pulmonary edema: fluid accumulation in lungs in extreme cases.\n- Acute withdrawal syndrome: severe opioid withdrawal symptoms including agitation, tachycardia, and hypertension.

Naloxone should be used with clinical judgment and monitoring.\n\n- Assess airway: ensure patency before and after administration.\n- Monitor vitals: watch for changes in blood pressure, heart rate, and respiration.\n- Re‑dose if needed: repeat dosing may be required due to shorter half‑life than many opioids.\n- Caution in chronic opioid users: anticipate withdrawal symptoms.\n- Avoid in patients with known hypersensitivity to naloxone.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Naloxone may interact with other agents that affect the central nervous system.\n\nMajor Interactions (Avoid):\n- Opioid agonists: concurrent high‑dose opioids can diminish reversal effectiveness.\n- MAO inhibitors: may increase risk of severe hypertension when combined with certain sympathomimetics.\n\nModerate Interactions (Monitor Closely):\n- Benzodiazepines: combined use may mask withdrawal signs.\n- Anticholinergic drugs: may exacerbate tachycardia or dry mouth.\n- Cardiovascular agents: monitor for additive effects on blood pressure.